Categories Analysis, Health Care, Trending Stocks

Hopes high for Mylan’s Upjohn merger even as epidemic mars short-term prospects

A new company called Viatris will be formed by combining Mylan with Upjohn

Drugmaker Mylan (NASDAQ: MYL) is all set for a transformation with its planned merger with Upjohn, the generic medicine business of Pfizer (PFE). The transaction, which is expected to close mid-2020, is of great significance for the company at a time when it is facing multiple challenges, including sales slump in North America and pricing issues.

Of late, Mylan has been pinning hope on its biosimilar business, with several candidates at different stages of development and neutropenia drug Fulphila recently securing FDA approval. The company has been gaining market share aided by the positive response to its biosimilar to Roche Holding’s cancer drug Herceptin. Ogivri was rolled out last year after a legal battle.

The Pros

These positive factors, combined with the Pfizer tie-up, should help the company regain strength this year. Incoming chief financial officer Sanjeev Narula, who is expected to assume office at the combined entity later this year, will have several key tasks to perform.

Stock Movement

Mylan’s stock was on the recovery path early this year, after last year’s dismal performance, but it pulled back last month amid the coronavirus-linked selloff. Market watchers predict a strong rebound in the latter part of the year and the majority of them recommend buying the stock.

Mylan (MYL) Q3 earnings surpass estimates; revenues miss

Currently, the main challenge facing the company is lingering concerns over last year’s lawsuit in which several generic drugmakers including Mylan were charged with price-fixing. The final outcome of the case could play a key role in deciding the company’s future, given the unfavorable market conditions including the falling prices of generic drugs in the US.

Q4 Profit up

Reflecting the strong demand across key markets, Mylan’s revenues grew 4% to $3.2 billion in the fourth quarter. Consequently, earnings, adjusted for one-off items, moved up 8% to $1.40 per share during the three-month period. While the bottom-line topped the Street view, revenues fell short of expectations.

Mylan’s stock, which has been in a free fall for more than a year, extended the losses in recent weeks as the COPID-19 crisis battered the markets. At $15.04, the shares closed the last trading session down 48% from last year. The stock contracted about 20% this year alone.

Most Popular

360 DigiTech (NASDAQ: QFIN) Q3 2021 Research Summary

The positive effects of widespread digitalization and e-commerce growth on China’s financial services industry became more pronounced during the pandemic as the movement restrictions drove more retail customers to online

Activision Blizzard (ATVI): Three reasons why this stock deserves to be on your radar

Shares of Activision Blizzard Inc. (NASDAQ: ATVI) were up 1.6% on Thursday. The stock has dropped 14% since the start of the year. The company has been in the news

IPO Alert: Here’s all you need to know about Remitly Global’s upcoming market debut

The emergence of technology-driven financial services is making people think beyond conventional banks when it comes to availing loans and transferring funds. In a move aimed at taking its business

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top